"There is a clear association between the use of GLPs and increased risks of food retention during upper endoscopy," Mathur ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Discover an untold biotech story and find out how Pfizer missed an opportunity in the GLP-1 market because of an exit in the ...

MangoRx aims to capitalize on growing demand for GLP-1 treatments to drive revenue growth and expand market share in the weight loss ...

It’s similar with multiple sclerosis. Actually, there are so many good drugs out there. A lot of the market has already been ...

Looking at the data from clinical trials of new GLP-1 agonists, it's clear that patients will need to stay on the drugs to ...

About 40% of U.S. adults suffer from obesity, and the cost of covering GLP-1 agonists and related anti-obesity drugs can be ...

Employers that cover GLP-1s are partnering with vendors to design benefits and manage lifestyle programs, but the "jury is ...

In an interview with Peers & Perspectives in Oncology, Sherry Shen, MD, discusses the GLP-1 agonists analyzed for weight ...

Breakthrough – or even better, revolutionary breakthrough – is perhaps the most overused term in drug development. But the ...

GLP-1 agonists, widely used for obesity and diabetes management, have been associated with a reduced risk of most ...

Vivani Medical today announced that Australian authorities approved a first-in-human clinical trial for its subdermal GLP-1 ...